REGLUTIDE® is a once-weekly injectable medication containing semaglutide, prescribed primarily for adults with type 2 diabetes to improve blood sugar control. It works by enhancing insulin release only when needed, lowering the liver’s glucose output, and slowing gastric emptying, which helps prevent post-meal glucose spikes. Additionally, semaglutide has demonstrated benefits in reducing the risk of major cardiovascular events for those with existing heart disease.
The usual regimen starts with 0.25mg weekly for the first four weeks, potentially increasing to 0.5mg or 1mg weekly as directed by a healthcare professional. Administration is via a prefilled injection pen, and strict adherence to prescribed use is essential.
REGLUTIDE® should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC), those diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or anyone allergic to semaglutide or its components. Common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation, though these often diminish over time. The medication must be refrigerated at 2°C to 8°C.
Concurrent use of REGLUTIDE® with other medications should be disclosed to your healthcare provider, and patients should discuss any medical conditions or allergies before starting therapy.
•Primary uses: Type 2 diabetes blood sugar management, reduction of cardiovascular event risk.
•Onset: Weekly dosing, gradual effect; duration supports stable blood sugar control.
•Warnings: Avoid use with family/personal history of MTC, MEN 2, or known allergy to ingredients.
•Risks: Gastrointestinal upset, rare risk of serious allergic reaction or thyroid tumors.
•Administration: Prefilled pen for subcutaneous injection; follow physician’s instructions closely.
Reviews
There are no reviews yet.